Paper17488686
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S and 23 others. Haematologica, 2007. Cited by 74 papers, by iCite.
Cite this record
ConductScience Library. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Papers, record 17488686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17488686
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
- PubMed
Topics36
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cell Transplantation | Major topic |
| Lymphoma, Non-Hodgkin | Major topic |
| Transplantation Conditioning | Major topic |
| Adult | |
| Aged | |
| Antibodies, Monoclonal | |
| Antilymphocyte Serum | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Busulfan | |
| Carmustine | |
| Combined Modality Therapy | |
| Cyclophosphamide | |
| Cytarabine | |
| Data Collection | |
| Disease-Free Survival | |
| Etoposide | |
| Female | |
| France | |
| Graft vs Host Disease | |
| Graft vs Leukemia Effect | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Melphalan | |
| Middle Aged | |
| Proportional Hazards Models | |
| Remission Induction | |
| Retrospective Studies | |
| Salvage Therapy | |
| Survival Analysis | |
| Survival Rate | |
| T-Lymphocytes | |
| Transplantation, Homologous | |
| Treatment Outcome | |
| Vidarabine | |
| Whole-Body Irradiation |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01208896 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17488679 | Current role of allogeneic stem cell transplantation in follicular lymphoma. | https://conductscience.org/library/papers/17488679 |
Source PubMed
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 29424927 | Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. | Cancer | 2018 | https://conductscience.org/library/papers/29424927 | PubMed |
| 27175243 | Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. | Leuk Suppl | 2012 | https://conductscience.org/library/papers/27175243 | PubMed |
| 26855152 | Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. | Bone Marrow Transplant | 2016 | https://conductscience.org/library/papers/26855152 | PubMed |
| 25985053 | Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. | Bone Marrow Transplant | 2015 | https://conductscience.org/library/papers/25985053 | PubMed |
| 25190696 | Non-Hodgkin's lymphomas, version 4.2014. | J Natl Compr Canc Netw | 2014 | https://conductscience.org/library/papers/25190696 | PubMed |
| 24534109 | Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. | Biol Blood Marrow Transplant | 2014 | https://conductscience.org/library/papers/24534109 | PubMed |
| 24315843 | A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. | Biol Blood Marrow Transplant | 2014 | https://conductscience.org/library/papers/24315843 | PubMed |
| 24043582 | Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. | Int J Hematol | 2013 | https://conductscience.org/library/papers/24043582 | PubMed |
| 23935024 | Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. | Haematologica | 2014 | https://conductscience.org/library/papers/23935024 | PubMed |
| 23813647 | Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. | Haematologica | 2013 | https://conductscience.org/library/papers/23813647 | PubMed |
| 23771004 | The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. | Bone Marrow Transplant | 2013 | https://conductscience.org/library/papers/23771004 | PubMed |
| 23691438 | Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status. | Cancer Biol Med | 2013 | https://conductscience.org/library/papers/23691438 | PubMed |
| 23556071 | Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience. | Ther Adv Hematol | 2011 | https://conductscience.org/library/papers/23556071 | PubMed |
| 23380340 | Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. | Biol Blood Marrow Transplant | 2013 | https://conductscience.org/library/papers/23380340 | PubMed |
| 23222387 | Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. | Bone Marrow Transplant | 2013 | https://conductscience.org/library/papers/23222387 | PubMed |
| 23063143 | Management of indolent lymphoma: where are we now and where are we going. | Blood Rev | 2012 | https://conductscience.org/library/papers/23063143 | PubMed |
| 22522568 | Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/22522568 | PubMed |
| 22312100 | Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22312100 | PubMed |
| 21641099 | Stem cell transplantation for indolent lymphoma: a reappraisal. | Blood Rev | 2011 | https://conductscience.org/library/papers/21641099 | PubMed |
| 21358679 | Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/21358679 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17488686
GET https://conductscience.org/api/papers/v1/17488686/authors?page=2